RAFAEL HOLDINGS INC. CLASS B COMMON STOCK

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

30 Sep 2026 07:00:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

11 Dec 2025 16:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

29 Oct 2025 16:24:40 By Nasdaq GlobeNewswire

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

28 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

16 Sep 2025 08:00:00 By Nasdaq GlobeNewswire

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

27 Aug 2025 08:00:00 By Nasdaq GlobeNewswire

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

18 Jun 2025 07:00:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

11 Jun 2025 07:00:00 By Nasdaq GlobeNewswire

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

04 Jun 2025 16:01:00 By Nasdaq GlobeNewswire

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

20 May 2025 16:01:00 By Nasdaq GlobeNewswire

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

05 May 2025 07:00:00 By Nasdaq GlobeNewswire

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

29 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

24 Apr 2025 16:15:00 By Nasdaq GlobeNewswire

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

26 Mar 2025 06:50:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

13 Mar 2025 17:50:30 By Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

06 Nov 2024 19:14:00 By Nasdaq GlobeNewswire

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

22 Aug 2024 06:50:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

14 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

13 Mar 2024 17:04:24 By Nasdaq GlobeNewswire